Betamethasone Dipropionate Emollient Spray vs Halobetasol Propionate Lotion

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: Glucocorticoid receptor · full Psoriasis pipeline

Betamethasone Dipropionate Emollient Spray · Sernivo

Marketed by Primus Pharmaceuticals and partners

Approved in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Halobetasol Propionate Lotion · Bryhali

Marketed by Bausch Health

Approved in Psoriasissmall molecule
Partial signal

NCT02514577 · Phase 3 · completed

The study was randomized, quadruple-blinded and vehicle-controlled, with 217 participants, and used a clinical Investigator's Global Assessment treatment-success endpoint at Week 8. The peer-reviewed report of the two Phase 3 trials states superiority over vehicle at Week 8 (36.5% (Study 1) vs vehicle, P<0.001), so the primary comparison was met.

Reported efficacy

Percentage of Participants With Treatment Success at Week 8: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 36.5% vs IDP-122 Vehicle Lotion 8.13% (met)

Result source: NCT02514577

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBetamethasone Dipropionate Emollient SprayHalobetasol Propionate Lotion
PASI 75—Not reported—Not reported
PASI 90—Not reported—Not reported
PASI 100—Not reported—Not reported
sPGA 0/1—Not reported36.5% vs 8.1%+28.4 vs placebowk 8 · n 143NCT02514577
9 other results
  • 38.4% vs 12.0% wk 8 · n 142 · Phase 3 · primary NCT02515097
  • 19.5% vs 6.7% wk 12 · n 143 · Phase 3 · secondary NCT02514577
  • 23.0% vs 9.3% wk 12 · n 142 · Phase 3 · secondary NCT02515097
  • 30.1% vs 7.9% wk 6 · n 143 · Phase 3 · secondary NCT02514577
  • 27.7% vs 4.3% wk 6 · n 142 · Phase 3 · secondary NCT02515097
  • 19.8% vs 2.8% wk 4 · n 143 · Phase 3 · secondary NCT02514577
  • 19.3% vs 0.2% wk 4 · n 142 · Phase 3 · secondary NCT02515097
  • 7.1% vs 0% wk 2 · n 143 · Phase 3 · secondary NCT02514577
  • 4.9% vs 0% wk 2 · n 142 · Phase 3 · secondary NCT02515097
DLQI, change—Not reported—Not reported

PASI 75

Betamethasone Dipropionate Emollient Spray
—Not reported
Halobetasol Propionate Lotion
—Not reported

PASI 90

Betamethasone Dipropionate Emollient Spray
—Not reported
Halobetasol Propionate Lotion
—Not reported

PASI 100

Betamethasone Dipropionate Emollient Spray
—Not reported
Halobetasol Propionate Lotion
—Not reported

sPGA 0/1

Betamethasone Dipropionate Emollient Spray
—Not reported
Halobetasol Propionate Lotion
36.5% vs 8.1%+28.4 vs placebowk 8 · n 143NCT02514577
9 other results
  • 38.4% vs 12.0% wk 8 · n 142 · Phase 3 · primary NCT02515097
  • 19.5% vs 6.7% wk 12 · n 143 · Phase 3 · secondary NCT02514577
  • 23.0% vs 9.3% wk 12 · n 142 · Phase 3 · secondary NCT02515097
  • 30.1% vs 7.9% wk 6 · n 143 · Phase 3 · secondary NCT02514577
  • 27.7% vs 4.3% wk 6 · n 142 · Phase 3 · secondary NCT02515097
  • 19.8% vs 2.8% wk 4 · n 143 · Phase 3 · secondary NCT02514577
  • 19.3% vs 0.2% wk 4 · n 142 · Phase 3 · secondary NCT02515097
  • 7.1% vs 0% wk 2 · n 143 · Phase 3 · secondary NCT02514577
  • 4.9% vs 0% wk 2 · n 142 · Phase 3 · secondary NCT02515097

DLQI, change

Betamethasone Dipropionate Emollient Spray
—Not reported
Halobetasol Propionate Lotion
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Betamethasone Dipropionate Emollient Spray: registry results are on file for Psoriasis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Betamethasone Dipropionate Emollient Spray: 0 of 4 rows · Halobetasol Propionate Lotion: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricHalobetasol Propionate Lotion
Dropout rate
9.8%a
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
show 2 more results
4.9%
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
0%0.05% lotion
NCT01610596 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.7%a
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
show 2 more results
1.4%
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
—0.05% lotion
NCT01610596 · Phase 2 · registry result, not featured evidence
Serious AEs
0.7%a
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
show 2 more results
1.4%
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
0%0.05% lotion
NCT01610596 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
0.05% lotiona
application site pain 8.3% (placebo 8.3%)
application site atrophy 5.6% (placebo 0%)
application site discoloration 2.8% (placebo 0%)
NCT01610596 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Halobetasol Propionate Lotion

sPGA 0/1 36.5% (n=143) vs 8.13% (n=74) placebo @ 8wk
responder rate · % of participants
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
show 9 more results
7.06% (n=143) vs 0% (n=74) placebo @ 2wk
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
19.81% (n=143) vs 2.77% (n=74) placebo @ 4wk
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
30.14% (n=143) vs 7.93% (n=74) placebo @ 6wk
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
19.48% (n=143) vs 6.69% (n=74) placebo @ 12wk
NCT02514577 · Phase 3 · monotherapy · Psoriasis · phase 3
38.41% (n=142) vs 11.99% (n=71) placebo @ 8wk
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
4.93% (n=142) vs 0% (n=71) placebo @ 2wk
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
19.26% (n=142) vs 0.2% (n=71) placebo @ 4wk
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
27.71% (n=142) vs 4.35% (n=71) placebo @ 6wk
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
23.04% (n=142) vs 9.34% (n=71) placebo @ 12wk
NCT02515097 · Phase 3 · monotherapy · Psoriasis · phase 3
PGA 0-1 30.6% (n=36) vs 0% (n=35) placebo @ 2.14wk0.05% lotion
responder rate · % of participants
NCT01610596 · Phase 2 · registry result, not featured evidence
BSA -0.3% (n=36) vs -0.1% (n=35) placebo @ 1.14wk0.05% lotion
absolute change · percentage points
NCT01610596 · Phase 2 · registry result, not featured evidence
show 1 more result
-1.3% (n=36) vs -0.2% (n=35) placebo @ 2.14wk0.05% lotion
NCT01610596 · Phase 2 · registry result, not featured evidence
Scaling 25% (n=36) vs 8.6% (n=35) placebo @ 1.14wk0.05% lotion
responder rate · % of participants
Scaling (Day 8)
NCT01610596 · Phase 2 · registry result, not featured evidence
Scaling 61.1% (n=36) vs 11.4% (n=35) placebo @ 2.14wk0.05% lotion
responder rate · % of participants
Scaling (Day 15)
NCT01610596 · Phase 2 · registry result, not featured evidence
PGA 2-point Improvement 13.9% (n=36) vs 0% (n=35) placebo @ 1.14wk0.05% lotion
responder rate · % of participants
NCT01610596 · Phase 2 · registry result, not featured evidence
show 1 more result
44.4% (n=36) vs 0% (n=35) placebo @ 2.14wk0.05% lotion
NCT01610596 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Betamethasone Dipropionate Emollient Spray's landscape · Halobetasol Propionate Lotion's landscape